与免疫检查点抑制剂相关的延迟免疫相关不良事件概况:现实世界的分析
Yana Yang1, Linman Li2, Jing Tian2
1Nursing Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Frontiers in pharmacology
|November 26, 2024
概括
延迟免疫相关不良事件 (irAEs) 可能发生在接受免疫检查点抑制剂 (ICI) 的患者中. 这项研究强调了迅速识别和管理这些晚发性毒性的重要性.
科学领域:
- 药物监督 药物监督 药物监督
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 与免疫相关的不良事件 (irAEs) 与免疫检查点抑制剂 (ICI) 常见.
- 晚期发病的IRAE是不太了解的,需要进一步描述.
- 这项研究调查了与ICI相关的延迟毒性.
研究的目的:
- 量化延迟IRA和ICI之间的相关性.
- 确定这些延迟毒性的临床特征.
- 为临床实践提供有关ICI相关不良事件的信息.
主要方法:
- 利用了来自FDA不良事件报告系统 (FAERS) 的2011-2023年数据.
- 使用了四种信号检测算法:ROR,PRR,BCPNN和MGPS.
- 在系统器官类 (SOC) 和首选术语 (PT) 层面分析了ICI和延迟IRE之间的关联.
主要成果:
- 在147,854个总病例中,确定了3738例延迟性IRE.
- 在ICI和胃肠道,新陈代谢,呼吸道和皮肤疾病之间发现了显著的关联.
- 肺炎和结肠炎是ICI疗法中最显著的PT信号;胃肠道疾病死亡比例最高.
结论:
- 一部分ICI患者经历了具有潜在严重后果的挑战性延迟IRAE.
- 早期检测和干预对于管理这些晚发性毒性至关重要.
- 药监数据为ICI安全概况提供了宝贵的见解.
相关概念视频
Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
359
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
359


